Greenphire, the global leader in financial lifecycle management for clinical trials, today unveiled the addition of the Patient-Powered Registry, designed to help foundations more effectively engage and support patient communities. Already the industry leader in removing barriers for clinical research participants, Greenphire leveraged processes rooted in cognitive neuroscience to identify engagement gaps in pre-trial activity and build technology which connects digital user experiences throughout the journey, galvanizing a new level of patient centricity.
The Patient-Powered Registry has been introduced at a time when foundations and advocacy organizations are seeking to gather insights from patients to drive research and are accelerating their use of digital technology to meet that need. The comprehensive mobile and web-based registry will allow disease-specific organizations to communicate with members – delivering patient insights such as condition-specific health information, employing interactive tools such as virtual surveys, and connecting and matching members with clinical trials that they may be interested in. Foundations can create and manage registry content quickly and easily, streamlining operations and improving analytics to enhance patient support and provide value-added data to key stakeholders such as their boards of directors.
"The Patient-Powered Registry has been a powerful resource for the Alliance, our members and people living with metastatic breast cancer," said Laurie Campbell, Executive Director of the Metastatic Breast Cancer Alliance. "Smaller organizations are not equipped with the staff and finances to build an in-house solution for connecting with patients. This registry is an efficient resource that is easy to use and enables us to truly dedicate our time and resources toward our mission of transforming and improving the lives of people living with metastatic breast cancer. Additionally, the registry reduces the burden on patients by pushing out helpful, relevant information, including insights and potential matches to clinical trials."